ADCs (Antibody-Drug Conjugates) and RDCs (Radionuclide Conjugates) are innovative drugs that have gained significant attention in recent years, demonstrating enormous potential in the field of oncology. They are referred to as the “magic bullets” of tumor-targeted therapy because they enable precise treatment while avoiding damage to normal cells. ADC drugs link antibodies with known effective … Read more
Last week, while introducing the “Breakthroughs and Innovations in Lung Cancer Treatment” from the “AACR 2021 Annual Report on Anti-Cancer Progress”（>> Click to review）, I mentioned a popular research topic—Antibody-Drug Conjugates (ADCs), which saw two new ADCs approved and two ADCs expanding their indications in 2021. Some readers expressed a desire to learn more about … Read more
ADC (Antibody-drug conjugate) is a new type of drug for cancer treatment. It is a complex formed by combining anti-tumor drugs with antibodies, allowing for precise delivery of the drug into tumor cells, thereby achieving targeted treatment of tumor cells. However, with the widespread application of ADCs, research has found that the issue of ADC … Read more
Source: YaoDu Written by: -7℃ Edited by: Wanzi ADC (Antibody Drug Conjugate) is a complex formed by linking cytotoxic drugs to monoclonal antibodies targeting tumors, which combines the characteristics of targeted drugs and chemotherapy drugs, enabling precise treatment. The concept of ADC drugs was proposed as early as 1900, but it remained theoretical for a … Read more
Introduction Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies that target specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs.ADCs consist of three main components: the antibody responsible for selectively recognizing cancer cell surface antigens, the … Read more
Known as magic bullets, ADCs have been highly praised in recent years. The design concept of these drugs is clear: to utilize the high specificity of antigen-antibody binding to selectively deliver toxins to antigen-positive cells, thereby selectively killing target cells and reducing damage to normal cells. However, like other drugs, the actual performance of ADCs … Read more
Introduction Antibody-drug conjugates(ADC) are formed by linking monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. ADC consists of three main components: the antibody responsible for selectively recognizing cancer cell surface antigens, the drug … Read more
Antibody-drug conjugates (ADC) are a novel type of medication that couples monoclonal antibodies, which specifically recognize cancer cell surface antigens, with cytotoxic chemotherapy drugs through specific linkers, exerting a significant tumor-killing effect. Currently, 15 ADC drugs, represented by trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd, DS-8201), have been approved globally, significantly changing the treatment landscape … Read more
Author: Cornflower This article is published with the author’s permission by Yiliao Tong. Please do not reproduce without authorization. Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a highly aggressive molecular subtype with poor prognosis. The advent of anti-HER2 targeted therapies has significantly improved its prognosis. Currently, international standards generally consider that … Read more
Open the public account and set it as a “star”. Follow us to learn more about cancer information!~ Breast Cancer In recent years, the treatment of breast cancer has been influenced by the practice of precision oncology, requiring personalized medical care based on specific tumor characteristics. The treatment of breast cancer primarily depends on the … Read more